Abstract
Hepatic diseases include all diseases that occur in the liver, including hepatitis, cirrhosis, hepatocellular carcinoma, etc. Hepatic diseases worldwide are characterized by high incidences of digestive system diseases, which present with subtle symptoms, are difficult to treat and have high mortality. Galectins are β-galactoside-binding proteins that have been found to be aberrantly expressed during hepatic disease progression. An increasing number of studies have shown that abnormal expression of galectins is extensively involved in hepatic diseases, such as hepatocellular carcinoma (HCC), liver cirrhosis, hepatitis and liver fibrosis. Galectins function as intracellular and extracellular hepatic disease regulators mainly through the binding of their carbohydrate recognition domain to glycoconjugates expressed in hepatocytes. In this review, we summarize current research on the various roles of galectins in cirrhosis, hepatitis, liver fibrosis and HCC, which may provide a preliminary theoretical basis for the exploration of new targets for the treatment of hepatic diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abu-Elsaa NM, Elkashef WF (2015) Modified citrus pectin stops progression of liver fibrosis by inhibiting galectin-3 and inducing apoptosis of stellate cells. Can J Physiol Pharmacol 94:554–562. https://doi.org/10.1139/cjpp-2015-0284
Bacigalupo ML, Manzi M, Espelt MV et al (2015) Galectin-1 triggers epithelial-mesenchymal transition in human hepatocellular carcinoma cells. J Cell Physiol 230:1298–1309. https://doi.org/10.1002/jcp.24865
Bacigalupo ML, Piazza VG, Cicconi NS et al (2019) Growth hormone upregulates the pro-tumorigenic galectin 1 in mouse liver. Endocr Connect 8:1108–1117. https://doi.org/10.1530/EC-19-0292
Balan V, Nangia-Makker P, Raz A (2010) Galectins as cancer biomarkers. Cancers 2:592–610. https://doi.org/10.3390/cancers2020592
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Bugianesi E (2007) Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 11:191–207. https://doi.org/10.1016/j.cld.2007.02.006
Cai Z, Zeng Y, Xu B, Gao Y, Wang S, Zeng J, Chen L, Huang A, Liu X, Liu J (2014) Galectin-4 serves as a prognostic biomarker for the early recurrence/metastasis of hepatocellular carcinoma. Cancer Sci 105:1510–1517. https://doi.org/10.1111/cas.12536
Camilleri M (2006) Gastroenterology and hepatology clinical research update: 2005–2006. Clin Gastroenterol Hepatol 4:1428–1433. https://doi.org/10.1016/j.cgh.2006.06.027
Cao ZQ, Guo XL (2016) The role of galectin-4 in physiology and diseases. Protein Cell 7:314–324. https://doi.org/10.1007/s13238-016-0262-9
Chabot S, Kashio Y, Seki M, Shirato Y, Nakamura K, Nishi N, Nakamura T, Matsumoto R, Hirashima M (2002) Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology 12:111–118. https://doi.org/10.1093/glycob/12.2.111
Chen S, Pu J, Bai J et al (2018) EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis. J Exp Clin Cancer Res 37:3. https://doi.org/10.1186/s13046-017-0670-6
Cho Y, Lee YB, Lee JH et al (2016) Modified AS1411 aptamer suppresses hepatocellular carcinoma by up-regulating galectin-14. PLoS ONE 11:e0160822. https://doi.org/10.1371/journal.pone.0160822
Chung EJ, Sung YK (2002) Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol Cells 14:382–387 PMID: 12521301
Darrow AL, Shohet RV, Maresh JG (2011) Transcriptional analysis of the endothelial response to diabetes reveals a role for galectin-3. Physiol Genomics 43:1144–1152. https://doi.org/10.1152/physiolgenomics.00035.2011
Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98–107. https://doi.org/10.1038/nri2925
Eisa NH, Ebrahim MA, Ragab M, Eissa LA, El-gayar AM (2015) Galectin-3 and matrix metalloproteinase-9: perspective in management of hepatocellular carcinoma. J Oncol Pharm Pract 21:323–330. https://doi.org/10.1177/1078155214532698
Endharti AT, Zhou YW, Nakashima I, Suzuki H (2005) Galectin-1 supports survival of naive T cells without promoting cell proliferation. Eur J Immunol 35:86–97. https://doi.org/10.1002/eji.200425340
Espelt MV, Croci DO, Bacigalupo ML et al (2011) Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth. Hepatology 53:2097–2106. https://doi.org/10.1002/hep.24294
Friedman SL (2008) Hepatic fibrosis: overview. Toxicology 254:120–129. https://doi.org/10.1016/j.tox.2008.06.013
Fujita K, Iwama H, Sakamoto T et al (2015) Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. Int J Oncol 46:2419–2430. https://doi.org/10.3892/ijo.2015.2941
Fujita K, Niki T, Nomura T et al (2017) Serum galectin-9 levels are correlated to liver fibrosis regardless of chronic inflammation or hepatocellular carcinoma complications. J Gastroenterol Hepatol. https://doi.org/10.1111/jgh.13851
Gao Y, Liu Y, Yang M, Guo X, Zhang M, Li H, Li J, Zhao J (2016) IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis. Oncotarget 7:33649–33661. https://doi.org/10.18632/oncotarget.9259
García MJ, Jurado F, San Segundo D et al (2015) Galectin-1 in stable liver transplant recipients. Transplant Proc 47:93–96. https://doi.org/10.1016/j.transproceed.2014.12.001
Golden-Mason L, McMahan RH, Strong M et al (2013) Galectin-9 functionally impairs natural killer cells in humans and mice. J Virol 87:4835–4845. https://doi.org/10.1128/JVI.01085-12
Golden-Mason L, Palmer BE, Kassam N et al (2009) Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 83:9122–9130. https://doi.org/10.1128/JVI.00639-09
Gudowska M, Gruszewska E, Cylwik B, Panasiuk A, Rogalska M, Flisiak R, Szmitkowski M, Chrostek L (2015) Galectin-3 concentration in liver diseases. Ann Clin Lab Sci 45:669–673 PMID: 26663797
Harwood NM, Golden-Mason L, Cheng L, Rosen HR, Mengshol JA (2016) HCV-infected cells and differentiation increase monocyte immunoregulatory galectin-9 production. J Leukoc Biol 99:495–503. https://doi.org/10.1189/jlb.5A1214-582R
Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 103:5060–5065. https://doi.org/10.1073/pnas.0511167103
Hirabayashi J, Kasai KI (1993) The family of metazoan metal-independent β-galactoside-binding lectins: structure, function and molecular evolution. Glycobiology 3:297–304. https://doi.org/10.1093/glycob/3.4.297
Ho MK, Springer TA (1982) Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. J Immunol 128:1221–1228
Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT (1999) Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 81:519–526
Hu CC, Jeng WJ, Chen YC et al (2017) Memory regulatory T cells increase only in inflammatory phase of chronic hepatitis B infection and related to galectin-9/Tim-3 interaction. Sci Rep 7:15280. https://doi.org/10.1038/s41598-017-15527-x
Iacobini C, Menini S, Ricci C et al (2009) Accelerated lipid-induced atherogenesis in galectin-3 deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 29:831–836. https://doi.org/10.1161/ATVBAHA.109.186791
Jeftic I, Jovicic N, Pantic J, Arsenijevic N, Lukic ML, Pejnovic N (2015) Galectin-3 ablation enhances liver steatosis, but attenuates inflammation and IL-33-dependent fibrosis in obesogenic mouse model of nonalcoholic steatohepatitis. Mol Med 21:453–465. https://doi.org/10.2119/molmed.2014.00178
Jiang JX, Chen X, Hsu DK et al (2011) Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo. Am J Physiol Gastrointest Liver Physiol 302:G439–G446. https://doi.org/10.1152/ajpgi.00257.2011
Jiang SS, Weng DS, Wang QJ et al (2014) Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med 12:273. https://doi.org/10.1186/s12967-014-0273-3
Jiang Z, Chen Y, Feng X, Jiang J, Chen T, Xie H, Zhou L, Zheng S (2013) Hepatic stellate cells promote immunotolerance following orthotopic liver transplantation in rats via induction of T cell apoptosis and regulation of Th2/Th3-like cell cytokine production. Exp Ther Med 5:165–169. https://doi.org/10.3892/etm.2012.801
Jiang ZJ, Shen QH, Chen HY, Yang Z, Shuai MQ, Zheng S (2018) Galectin-1 Restores Immune Tolerance to Liver Transplantation Through Activation of Hepatic Stellate Cells. Cell Physiol Biochem 48:863–879. https://doi.org/10.1159/000491955
Jiang ZJ, Shen QH, Chen HY, Yang Z, Shuai MQ, Zheng SS (2019) Galectin-1 gene silencing inhibits the activation and proliferation but induces the apoptosis of hepatic stellate cells from mice with liver fibrosis. Int J Mol Med 43:103–116. https://doi.org/10.3892/ijmm.2018.3950
Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA (2007) The AP1—dependent secretion of galectin-1 by Reed Sternbergcells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 104:13134–13139. https://doi.org/10.1073/pnas.0706017104
John S, Mishra R (2016) Galectin-9: From cell biology to complex disease dynamics. J Biosci 41:507–534. https://doi.org/10.1007/s12038-016-9616-y
Kared H, Fabre T, Bedard N, Bruneau J, Shoukry NH (2013) Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog 9:e1003422. https://doi.org/10.1371/journal.ppat.1003422
Karlsen AE, Størling ZM, Sparre T et al (2006) Immune-mediated beta-cell destruction in vitro and in vivo-A pivotal role for galectin-3. Biochem Biophys Res Commun 344:406–415. https://doi.org/10.1016/j.bbrc.2006.03.105
Kobayashi K, Morishita A, Iwama H et al (2015) Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. Oncol Rep 34:1761–1770. https://doi.org/10.3892/or.2015.4197
Kondoh N, Hada A, Ryo A, Shuda M, Arai M, Matsubara O, Kimura F, Wakatsuki T, Yamamoto M (2003) Activation of Galectin-1 gene in human hepatocellular carcinoma involves methylation-sensitive complex formations at the transcriptional upstream and downstream elements. Int J Oncol 23:1575–1583
Leung Z, Ko FCF, Tey SK et al (2019) Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. J Exp Clin Canc Res 38:423. https://doi.org/10.1186/s13046-019-1402-x
Li J, Sun RR, Yu ZJ, Liang H, Shen S, Kan Q (2015) Galectin-1 modulates the survival and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity in human hepatocellular carcinoma cells. Cancer Biother Radiopharm 30:336–341. https://doi.org/10.1089/cbr.2015.1857
Li Y, Komai-Koma M, Gilchrist DS, Hsu DK, Liu FT, Springall T, Xu D (2008) Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation. J Immunol 181:2781–2789. https://doi.org/10.4049/jimmunol.181.4.2781
Li Z, Soloski MJ, Diehl AM (2005) Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 42:880–885. https://doi.org/10.1002/hep.20826
Liang Y, Chen J, Zhang Y, Zhang W (2015) Expression of galectin-9 mRNA in hepatocellular carcinoma. Int J Clin Exp Pathol 8:15100–15105
Liu Y, Ji H, Zhang Y, Shen X, Gao F, He X, Li GA, Busuttil RW, Kuchroo VK, Kupiec-Weglinski JW (2015) Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury. J hepatol 62:563–572. https://doi.org/10.1016/j.jhep.2014.10.034
Liu YM, Chen Y, Li JZ, Gong JP (2014) Up-regulation of Galectin-9 in vivo results in immunosuppressive effects and prolongs survival of liver allograft in rats. Immunol Lett 162:217–222. https://doi.org/10.1016/j.imlet.2014.09.002
Lu LH, Nakagawa R, Kashio Y, Ito A, Shoji H, Nishi N, Hirashima M, Yamauchi A, Nakamura T (2007) Characterization of galectin-9-induced death of Jurkat T cells. J Biochem 141:157–172. https://doi.org/10.1093/jb/mvm019
Lv K, Zhang Y, Zhang M, Zhong M, Suo Q (2013) Galectin-9 promotes TGF-β1-dependent induction of regulatory T cells via the TGF-beta/Smad signaling pathway. Mol Med Rep 7:205–210. https://doi.org/10.3892/mmr.2012.1125
Ma X, Hua J, Li Z (2008) Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 49:821–830. https://doi.org/10.1016/j.jhep.2008.05.025
Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T (2008) Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 38:1098–1111. https://doi.org/10.1111/j.1872-034X.2008.00387.x
Matsuoka N, Kozuru H, Koga T et al (2019) Galectin-9 in autoimmune hepatitis: correlation between serum levels of galectin-9 and M2BPGi in patients with autoimmune hepatitis. Medicine. https://doi.org/10.1097/MD.0000000000016924
Mcglynn KA, Petrick JL, London WT (2015) Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 19:223–238. https://doi.org/10.1016/j.cld.2015.01.001
McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, Allen TM, Gretch DR, Rosen HR (2011) Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 121:821–821. https://doi.org/10.1172/JCI43127
Mengshol JA, Golden-Mason L, Arikawa T et al (2010) Crucial role for Kupffer cell-derived Galectin-9 in regulation of t cell immunity in Hepatitis C infection. PLoS ONE 5:e9504. https://doi.org/10.1371/journal.pone.0009504
Moiseeva EP, Spring EL, Baron JH, de Bono DP (1999) Galectin 1 modulates attachment, spreading and migration of cultured vascular smooth muscle cells via interactions with cellular receptors and components of extracellular matrix. J Vasc Res 36:47–58. https://doi.org/10.1159/000025625
Nakanishi Y et al (2008) Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol Res 38:1241–1251. https://doi.org/10.1111/j.1872-034X.2008.00395.x
Newlaczyl AU, Yu LG (2011) Galectin-3–A jack-of-all-trades in cancer. Cancer Lett 313:123–128. https://doi.org/10.1016/j.canlet.2011.09.003
Nomoto K, Nishida T, Nakanishi Y, Fujimoto M, Takasaki I, Tabuchi Y, Tsuneyama K (2012) Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease. Sci World J 2012:959824. https://doi.org/10.1100/2012/959824
Nomoto K, Tsuneyama K, Abdel Aziz HO, Takahashi H, Murai Y, Cui ZG, Fujimoto M, Kato I, Hiraga K, Hsu DK, Liu FT, Takano Y (2006) Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. J Pathol 210:469–477. https://doi.org/10.1002/path.2065
Ordoñez R, Carbajo-Pescador S, Prieto-Dominguez N, García-Palomo A, González-Gallego J, Mauriz JL (2014) Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG 2 liver cancer cells. J Pineal Res 56:20–30. https://doi.org/10.1111/jpi.12092
Pang J, Rhodes DH, Pini M, Akasheh RT, Castellanos KJ, Cabay RJ, Cooper D, Perretti M, Fantuzzi G (2013) Increased adiposity, dysregulated glucose metabolism and systemic inflammation in galectin-3 KO mice. PLoS ONE 8:e57915. https://doi.org/10.1371/journal.pone.0057915
Pejnovic N, Jeftic I, Jovicic N, Arsenijevic N, Lukic ML (2016) Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis. World J Gastroenterol 22:9706–9717. https://doi.org/10.3748/wjg.v22.i44.9706
Pejnovic NN, Pantic JM, Jovanovic IP et al (2013a) Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes 62:1932–1944. https://doi.org/10.2337/db12-0222
Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Djukic ALJ, Arsenijevic NN, Lukic ML (2013b) Galectin-3 is a regulator of metaflammation in adipose tissue and pancreatic islets. Adipocyte 2:266–271. https://doi.org/10.4161/adip.24881
Peng Y, Ye Y, Jia J et al (2018) Galectin-1-induced tolerogenic dendritic cells combined with apoptotic lymphocytes prolong liver allograft survival. Int Immunopharmacol 65:470–482. https://doi.org/10.1016/j.intimp.2018.10.019
Perillo NL, Marcus ME, Baum LG (1998) Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 76:402–412. https://doi.org/10.1007/s001090050232
Potikha T, Ella E, Cerliani JP, Mizrahi L, Pappo O, Rabinovich GA, Galun E, Goldenberg DS (2016) Galectin-1 is essential for efficient liver regeneration following hepatectomy. Oncotarget 7:31738–31754. https://doi.org/10.18632/oncotarget.9194
Qian Y, Liu Z, Geng X (2008) Lack of protection of ischaemic preconditioning in the rat model of major hepatectomy with ischaemia reperfusion injury. Asian J Surg 31:140–147. https://doi.org/10.1016/S1015-9584(08)60075-5
Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, Iacobelli S (2002) Galectins and their ligands: amplifiers, silencers of tuners of the inflammatory response? Trends Immunol 23:313–320. https://doi.org/10.1016/s1471-4906(02)02232-9
Rosen HR (2013) Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest 123:4121–4130. https://doi.org/10.1172/JCI67714
Safadi R, Friedman SL (2002) Hepatic fibrosis–role of hepatic stellate cell activation. Med Gen Med 4:27
Sato H, Ozawa K, Iwata S et al (2005) Role of bcl-2 mRNA in homeostatic proliferation in circulating T-cells in human liver transplant patients after T-cell depletion. J Surg Res 127:123–130. https://doi.org/10.1016/j.jss.2005.03.008
Scholzen A, Mittag D, Rogerson SJ, Cooke BM, Plebanski M (2009) Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGF-beta. PLoS Pathog 5:e1000543. https://doi.org/10.1371/journal.ppat.1000543
Serizawa N, Tian J, Fukada H et al (2015) Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. Lab Invest 95:1145–1156. https://doi.org/10.1038/labinvest.2015.77
Sideras K, Biermann K, Verheij J et al (2017) PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology 6:e1273309. https://doi.org/10.1080/2162402X.2016.1273309
Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, Tornillo L, Capasso M, Tiribelli C, Iolascon A (2010) Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol med 16:102. https://doi.org/10.2119/molmed.2009.00119
Su YC, Davuluri GVN, Chen CH, Shiau DC, Chen CC, Chen CL, Chang CP (2016) Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma. PLoS ONE 11:e0148408. https://doi.org/10.1371/journal.pone.0148408
Tang ZH, Liang S, Potter J, Jiang X, Mao HQ, Li Z (2013) Tim-3/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J Immunol 190:1788–1796. https://doi.org/10.4049/jimmunol.1202814
Ulu M, Alacacioglu A, Yuksel E, Pamukk BO, Bozkaya G, Ari A, Yuksel A, Sop G (2015) Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis. Saudi J Gastroentero 21:47–50. https://doi.org/10.4103/1319-3767.151228
Uluca Ü, Şen V, Ece A et al (2015) Serum galectin-3 levels in children with chronic hepatitis B infection and inactive hepatitis B carriers. Med Sci Monitor 21:1376–1380. https://doi.org/10.12659/MSM.894035
Wanninger J, Weigert J, Wiest R et al (2011) Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine 55:435–440. https://doi.org/10.1016/j.cyto.2011.06.001
Wu H, Chen P, Liao R et al (2012) Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection. J Gastroen Hepatol 27:1312–1319. https://doi.org/10.1111/j.1440-1746.2012.07130.x
Wu MH, Chen YL, Lee KH et al (2017) Glycosylation-dependent galectin-1/neuropilin-1 interactions promote liver fibrosis through activation of TGF-β-and PDGF-like signals in hepatic stellate cells. Sci Rep 7:11006. https://doi.org/10.1038/s41598-017-11212-1
Yang F, Hu Y, Liu HX, Wan YJ (2015a) MiR-22-silenced cyclin A expression in colon and liver cancer cells is regulated by bile acid receptor. J Biol Chem 290:6507–6515. https://doi.org/10.1074/jbc.M114.620369
Yang Q, Jiang W, Zhuang C, Geng Z, Hou C, Huang D, Wang X (2015b) microRNA-22 downregulation of galectin-9 influences lymphocyte apoptosis and tumor cell proliferation in liver cancer. Oncol Rep 34:1771–1778. https://doi.org/10.3892/or.2015.4167
Yang RY, Hsu DK, Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93:6737–6742. https://doi.org/10.1073/pnas.93.13.6737
Ye Y, Wang W, Zhang W et al (2019) Galectin-1 attenuates hepatic ischemia reperfusion injury in mice. Int Immunopharmacol 77:105997. https://doi.org/10.1016/j.intimp.2019.105997
Ye Y, Yan S, Jiang G, Zhou L, Xie H, Xie X, Yu X, Ding Y, Tian J, Dai Y, Zheng S (2013) Galectin-1 prolongs survival of mouse liver allografts from Flt3L-pretreated donors. Am J Transplant 13:569–579. https://doi.org/10.1111/ajt.12088
You Y, Tan JX, Dai HS, Chen HW, Xu XJ, Yang AG, Zhang YJ, Bai LH, Bie P (2016) MiRNA-22 inhibits oncogene galectin-1 in hepatocellular carcinoma. Oncotarget 7:7099–57116. https://doi.org/10.18632/oncotarget.10981
Zhang AB, Peng YF, Jia JJ, Nie Y, Zhang SY, Xie HY, Zhou L, Zheng SS (2019) Exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation. J Zhejiang Univ Sci B 20:605–612. https://doi.org/10.1631/jzus.B1900051
Zhang PF, Li KS, Shen YH et al (2016) Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. Cell Death Dis 7:e2201. https://doi.org/10.1038/cddis.2015.324
Zhang ZY, Dong JH, Chen YW, Wang XQ, Li CH, Wang J, Wang GQ, Li HL, Wang XD (2012) Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac J Cancer Prev 13:2503–2509. https://doi.org/10.7314/apjcp.2012.13.6.2503
Zhao J, Fan YC, Liu XY, Zhao ZH, Li F, Wang K (2017) Hypermethylation of the galectin-3 promoter is associated with poor prognosis of acute-on-chronic hepatitis B liver failure. Dig Liver Dis 49:664–671. https://doi.org/10.1016/j.dld.2017.01.158
Zheng D, Hu Z, He F, Gao C, Xu L, Zou H, Wu Z, Jiang X, Wang J (2014) Downregulation of galectin-3 causes a decrease in uPAR levels and inhibits the proliferation, migration and invasion of hepatocellular carcinoma cells. Oncol Rep 32:411–418. https://doi.org/10.3892/or.2014.3170
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sun, MJ., Cao, ZQ. & Leng, P. The roles of galectins in hepatic diseases. J Mol Hist 51, 473–484 (2020). https://doi.org/10.1007/s10735-020-09898-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10735-020-09898-1